US Pharma MarketingVedanta gets $60M to finish Phase 3 for C. diff microbiome therapy
Investors are pumping more money into one of the microbiome field's longest-standing biotechs to push it toward a Phase 3 readout in C. difficile next year. Cambridge, MA-based Vedanta Biosciences said Thursday its two main ...
Investors are pumping more money into one of the microbiome field's longest-standing biotechs to push it toward a Phase 3 readout in C. difficile next year.
Cambridge, MA-based Vedanta Biosciences said Thursday its two main ...
Source: Endpoints News